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INTRODUCTION
Androgen deprivation therapy (ADT),
as a standard treatment for metastatic
prostate cancer (PCa), is initially effective
in reducing tumor burden, palliating
symptoms and improving overall sur-
vival. However, patients will eventually
experience disease progression and de-
velop castration-resistant prostate cancer
(CRPC) within 1–3 years. CRPC patients
have a poor prognosis, with a median
survival of ~30 months (1). On the basis
of recent insights in the role of androgen
receptor (AR) signaling in CRPC, several
new therapeutic approaches are now
being tested in CRPC (2). Abiraterone, a
CYP17 inhibitor, was recently approved
for chemotherapy-resistant CRPC, and a
number of (other) drugs interfering with
AR signaling are now being tested in a
clinical trial. Until now, there is no clear
way to individualize these new thera-
pies. This step might be possible if we
better understand the various mecha-
nisms that lead to CRPC. Hence, an indi-
vidualized treatment in CRPC on the
basis of individual molecular tumor pro-
filing is needed to raise the benefit of
treatment. Furthermore, molecular tumor
profiling may provide an opportunity to
develop and implement novel innovative
drugs (3,4).
Despite ADT achieving castrate levels
of androgens in peripheral blood, intra-
tumoral androgen levels found in CRPC
tissue are sufficient to activate androgen-
mediated signaling pathways. ADT has
only a moderate effect on the levels of
adrenal androgens dehydroepiandro -
sterone (DHEA) and androstenedione
(AND) (5–7). Therefore, intratumoral
steroidogenesis (that is, the conversion of
adrenal androgens into the potent andro-
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gen testosterone) was suggested as a
cause for disease progression.(2) Many
recent publications have provided evi-
dence for the upregulation of steroido-
genic enzymes on the mRNA and protein
level in CRPC compared with primary
PCa. In addition, similar levels of T and
dihydrotestosterone (DHT) were found
in CRPC tissue/cells compared with pri-
mary PCa (8–12). The androgen depend-
ency of CRPC is clearly demonstrated by
the fact that CRPC patients still respond
to additional endocrine treatments, for
example, MDV3100 (enzalutamide), a
novel antiandrogen that blocks AR
translocation and transcriptional activity
(13), and Abiraterone (ZYTIGA), a
CYP17A1 inhibitor that blocks the con-
version of pregnenolone and proges-
terone into the 17-hydroxylated form of
pregnenolone and progesterone and then
furthermore influences the conversion
into downstream androgens (14).
Previous studies have revealed that
the gene encoding AKR1C3, an enzyme
involved in the conversion of adrenal an-
drogens into T, is often upregulated in
CRPC (8,15). We hypothesize that
AKR1C3 could be a marker for intratu-
moral steroidogenesis and subsequently
could become a target for secondary hor-
monal treatment of CRPC. In this study,
we phenotypically and functionally vali-




Human prostate specimens were col-
lected at the time of surgery with the ap-
proval of the local ethics committee of
the Radboud University Nijmegen Med-
ical Center (RUNMC). CRPC tissues
were obtained by transurethral resection
of the prostate after extensive local pro-
gression under hormonal therapy. Be-
nign prostatic hyperplasia (BPH) speci-
mens were obtained from transurethral
resection of the prostate or open prosta-
tectomy. Normal prostate and primary
PCa tissues were obtained by radical
prostatectomy. Primary PCa cases were
selected from patients without any previ-
ous hormonal treatment. The specimens
were snap-frozen in liquid nitrogen or
formalin fixed and paraffin embedded.
Tissues were processed by step section-
ing, and the samples for analysis were
selected after histopathological confirma-
tion of the tissue to be CRPC, primary
PCa, BPH or normal prostate.
Real-Time Polymerase Chain Reaction
TRIzol-extracted total RNA (2 μg) was
treated with DNase I, and cDNA was syn-
thesized by using random hexamer
primers and SuperScript II-MMLV reverse
transcriptase (Invitrogen; Life Technolo-
gies, Carlsbad, CA, USA). The reverse
transcriptase (RT) reaction (30 μL) was di-
luted four times in H2O (milliQ). Gene ex-
pression was determined by SYBR Green
qPCR (quantitative polymerase chain re-
action) by using SYBR Green PCR mix
(Roche Diagnostics, Mannheim, Ger-
many) and 2 μL cDNA as a template.
RNA not subjected to reverse transcrip-
tase was used as a negative control for
PCR amplification. Gene-specific primers
were used as described previously de-
scribed (15). qPCR was performed on a
LightCycler LC480 instrument (Roche Di-
agnostics) by using the following amplifi-
cation conditions: 5 min 95°C, followed
by 45 cycles of 10 s at 95°C, 20 s at 60°C
and 20 s at 72°C. Crossing-point (Cp) 
values were determined by using 
LightCycler 480 SW 1.5 software (Roche
Diagnostics). Hypoxanthine ribosyltrans-
ferase (HPRT) expression was used for
normalization (16). Relative gene expres-
sion levels were calculated according to
the model described by Pfaffl (17).
Western Blot Analysis
Total protein extracts were collected in
Laemmli lysis buffer (2% sodium dodecyl
sulfate [SDS], 60 mmol/L glycine, pH 6.8,
1 mmol/L CaCl2 and 300 mmol/L 
β-mercaptoethanol). Proteins were sepa-
rated in 10% SDS-PAGE (sodium dodecyl
sulfate–polyacrylamide gel electrophore-
sis), transferred to a polyvinylidene fluo-
ride (PVDF) transfer membrane (Amer-
sham Hybond-P; GE Healthcare Europe
GmbH, Freiburg, Germany) and probed
with a monoclonal mouse-anti-human
AKR1C3 antibody (NP6.G6.A6, 1:1,000;
Abcam, Cambridge, UK) and anti-β-actin
(1:5,000; Sigma-Aldrich Chemie B.V.,
Zwijndrecht, the Netherlands) for loading
control. The signal was detected by ECL
Plus Western Blotting Detection System
(GE Healthcare) according to the manu-
facturer’s protocol. Protein expression
levels were obtained after densitometric
scanning of the ECL films on a GS-690
densitometer (Bio-Rad Laboratories B.V.,
Veenendaal, the Netherlands).
Immunohistochemistry
Paraffin-embedded tissues were used
for immunohistochemistry. Kidney and
heart were used as AKR1C3-positive and
-negative control tissues, respectively.
The protocol was slightly modified from
a previous study (18). Briefly, 5-μm tissue
sections were cut, mounted onto Super-
frost plus object slides and then baked at
60°C for 1 h. After deparaffination, anti-
gen retrieval was performed with
10 mmol/L sodium citric acid buffer
(pH 6.0) at 95°C for 1 h. Nonspecific
binding was blocked by incubating the
tissue sections in 0.1 mol/L Tris-HCl 
(pH 7.6) containing 10% rabbit serum for
2 h. Human AKR1C3 was detected by
monoclonal mouse NP6G6.A6 antibody
(Abcam) at a 1:1,000 dilution in the
blocking buffer. Primary antibody was
incubated overnight at 4°C in a moist
chamber. Rabbit anti-mouse peroxidase
secondary antibody was applied for 1 h
at room temperature. DAB-H2O2 (Im-
munoLogic BV, Duiven, the Netherlands)
substrate was added to the slides and in-
cubated at room temperature for an ad-
ditional 4 min. Tissue sections were
counterstained lightly with hematoxylin.
Slides were dehydrated and sealed with
Permount Mounting Media (SP15-500;
Fisher Scientific, Hampton, NH, USA)
for  visualization by light microscopy.
Cell Culture
Prostate cell lines are described in Sup-
plementary Table S1. All cells were cultured
in RPMI-1640 medium (31870; Invitrogen;
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Life Technologies), supplemented with 
L-glutamine and 10% fetal bovine serum
(F7524; Sigma-Aldrich), without antibi-
otics, except LAPC4, Ep156T and 
DuCaP-N, which were cultured as de-
scribed previously (19–21). Cells were
maintained in a humidified atmosphere at
37°C and 5% CO2. For DuCaP experi-
ments, we added 100 U penicillin/ mL
and 100 μg streptomycin/ mL (Invitrogen;
Life Technologies) in the medium. The
DuCaP passage numbers were 35–55.
Proliferation Assay
Cells were incubated in RPMI-1640
supplemented with 10% charcoal-
stripped serum (CSS), supplemented
with 1 nmol/L to 10 μmol/L DHEA
(D4000; Sigma-Aldrich), to resemble cir-
culating adrenal androgen conditions in
ADT and CRPC patients (5,22). Cells
were seeded in 96-wells plates (Corning
B.V. Life Sciences, Amsterdam, the
Netherlands) at a density of 10,000 cells
per well. Half of the medium was
changed every forth day. A standard
MTT (dimethylthiazolyldiphenyltetra-
zolium bromide; Sigma-Aldrich) assay
was performed every forth day up to d
16; readings were  performed on a Victor3
multimeter (PerkinElmer, Waltham, MA,
USA). Experiments were performed in
triplicate and were repeated at least three
times. Relative cell numbers were calcu-
lated from optical density  values.
Radioimmunoassay
Conditioned media were collected
from the cells that were incubated in six-
well plates (Corning) with 100,000
cells/well. AND, T and DHT were as-
sessed from conditioned medium by
3H-radioimmunoassay after prepurifica-
tion by using paper chromatography of
ether extracts of the samples, including
correction for procedural losses, as de-
scribed previously (23–25). To summa-
rize briefly, before extraction, 3H-AND,
3H-T or 3H-DHT was added to correct
for procedural losses. After chromatog-
raphy, the location of the AND, T or
DHT zone was identified by radiochro-
matogram scanning, and the zone was
cut out and soaked in buffer. The recov-
ered radioactivity was measured by liq-
uid scintillation counting of an aliquot
from the eluate. Subsequently, AND, T
or DHT tracer and antiserum were
added, and after incubation, free and
bound tracers were separated by means
of dextrane-coated charcoal. Antibody-
bound radioactivity was assessed by liq-
uid scintillation counting of the super-
natant. The calculations were performed
by special software designed for correc-
tion of the mass and radioactive contri-
bution of the recovery tracer in the ra-
dioimmunoassay. The detection limit for
AND was 50 pmol/L when using a sam-
ple volume of 1 mL. The intra-assay co-
efficient of variation (CV) between-run
was 7.6% at a level of 4.2 nmol/L. The
detection limit for T was 16 pmol/L
when using a sample volume of 1 mL.
The CV between-run was 5.8% at a level
of 6.5 nmol/L. Accuracy was assessed
by measurement of quality-control sam-
ples in which the T levels had been as-
sessed by gas chromatography– mass
spectrometry. A bias of –1.3 ± 1.7% (stan-
dard error of the mean) compared with
the target value was observed.
Intervention Experiment
Indomethacine (INN) (I7378; Sigma-
Aldrich), an AKR1C3 inhibitor (26), was
diluted in ethanol. INN concentrations of
10 and 25 μmol/L were added to DuCaP
cell culture medium every 2 d. The con-
trol group was treated with vehicle (that
is, ethanol equal to the amount of etha-
nol in the 25 μmol/L INN group). Prolif-
eration and androgen levels were mea-
sured as explained above.
Apoptosis Assay
DuCaP cells (1 × 105/well) were grown
on clear-bottom black 96-well plates
(Corning) for 24 h. Then the cells were
treated with INN as mentioned above.
Caspase-3/7 activity was measured at
2–48 h after treatment by using the 
Apo-ONE assay (Promega Benelux B.V.,
Leiden, the Netherlands) according to
the manufacturer’s instructions. Experi-
ments were done twice in triplicate.
Cell Cycle Analysis
DuCaP cells (2 × 106) were grown and
treated with INN for 2 d. Attached and
floating cells were harvested in Hank’s
Balanced Salt Solution (Invitrogen; Life
Technologies) and fixed in 70% ethanol
on ice. Samples were treated with 
100 μg/mL Ribonuclease A (Sigma-
Aldrich) for 40 min at 37°C, and DNA
was stained with 40 μg/mL propidium
iodide (Sigma-Aldrich). Cells (100,000)
were analyzed on a FC500 flow cytome-
ter (Beckman Coulter Nederland B.V.,
Woerden, the Netherlands). Experiments
were performed two times.
Statistical Analysis
The correlation of AKR1C3 mRNA
level by qPCR and protein level by
Western blot was analyzed using linear
regression. The effect of DHEA and
INN treatment on cell proliferation and
apoptosis was analyzed by using a one-
way analysis of variance (ANOVA) test
with post hoc Dunnett correction and
two-way ANOVA tests with post hoc
Bonferroni correction on relative cell
numbers on d 0 compared with other
time points. Androgen level was ana-
lyzed using a one-way ANOVA test
with post hoc Dunnett correction.
Graphpad Prism 5 software was used
and p values <0.05 were considered sta-
tistically significant.
All supplementary materials are available
online at www.molmed.org.
RESULTS
AKR1C3 Is Overexpressed in a Subset
of CRPC Cases
A total of 15 BPH or nonmalignant
prostate, 30 primary PCa and 44 CRPC
samples were evaluated for AKR1C3
mRNA and protein expression levels. All
normal and primary PCa samples had
low AKR1C3 mRNA expression, whereas
a subset of CRPC cases showed upregu-
lation of AKR1C3 at the RNA level (Fig-
ure 1A). AKR1C3 mRNA expression was
confirmed by Western blot analysis (Fig-
ure 1B). There was a correlation between
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AKR1C3 mRNA and protein levels (r2 =
0.39, p < 0.0001). Western blot analysis re-
sults were confirmed by immunohisto-
chemistry. One (of 30) primary PCa cases
displayed weak AKR1C3 immunoreac-
tivity (Figure 1C, image 1). Strong
AKR1C3 immunohistochemical staining
was found in 34% (15 of 44) of CRPC
cases (Figure 1C, image 2), and a moder-
ate to weak staining was found in 50%
(22 of 44) of CRPC cases (Figure 1C,
image 3). The remainder of CRPC cases
was negative for AKR1C3 (Figure 1C,
image 4). The immunohistochemical
staining also showed that AKR1C3 pro-
tein was predominantly expressed in
cancer (epithelial) cells and not in the
stromal cells (Figure 1C).
AKR1C3 Expression in PCa Cell Lines
We measured AKR1C3 expression in
several prostate (cancer) cell lines. Of all
tested cell lines, DuCaP and VCaP cells
had the highest AKR1C3 protein expres-
sion (Figure 2). These cell lines are
 propagated under very low androgen
levels (27); hence, they can be consid-
ered models mimicking CRPC. Both cell
lines express a wild-type AR (28). We se-
lected the DuCaP cell line for further
 experiments.
DHEA Stimulated DuCaP Proliferation
and DHEA Conversion into T and DHT
DuCaP growth was stimulated in
DHEA-supplemented medium. Maximal
DuCaP proliferation was reached at
100 nmol/L DHEA (Figure 3B). This
 concentration was used for further ex-
periments. DuCaP proliferation in-
creased exponentially in 100 nmol/L
DHEA-supplemented medium (Fig-
ure 3C). Proliferating DuCaP cells were
capable of converting DHEA into AND
and the potent androgens T and DHT
(Figure 3D). No androgens were detected
in conditioned media from cells grown
without DHEA supplementation at any
time point (not shown). AKR1C3 protein
levels were downregulated during
DHEA-stimulated proliferation (Fig-
ure 3E).
Interfering with AKR1C3 Activity
Diminishes Cell Proliferation and
Induces Apoptosis
Recently, an enzyme inhibitor for
AKR1C3 (INN) was described (26,29).
Treatment of DuCaP cells with INN at
10 μmol/L significantly inhibited cell
proliferation at d 16. The more pro-
nounced effect was seen at 25 μmol/L
INN (Figure 4A). This result was accom-
panied by a reduced conversion of
DHEA into T and DHT, as shown by the
significant accumulation of the precursor
molecule AND and the decrease in T and
DHT levels in the INN-treated samples
at 16 d of treatment (Figure 4B). Induc-
tion of caspase-3 and -7 activity, an early
apoptotic process, was already observed
after 2-h INN treatment (Figure 4C). Cell
cycle distribution (that is, percentage of
cycling cells in the G1, S and G2/M
phase) did not change significantly after
48 h of INN treatment (Figure 4D). How-
ever, an INN dose-dependent increasing
number of cells appeared as a sub-G1
population, with the latter being an indi-
cator for apoptosis (30) (Figure 4D,
arrow).
DISCUSSION
Recent studies on steroidogenic en-
zymes in CRPC have shown that enzymes
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Figure 1. AKR1C3 expression in clinical samples. (A) Relative AKR1C3 mRNA expression in
tissue samples. AKR1C3 qPCR data were normalized to the HPRT housekeeping gene lev-
els. (B) Example of AKR1C3 Western blot analysis using protein extracts derived from fresh-
frozen tissue specimens. β-Actin was used for normalization purposes; the ratio of
AKR1C3/β-actin expression was determined after optical scanning of the Western blots.
One primary PCa case was used as a reference (ratio set to 1). (C) AKR1C3 immunohisto-
chemistry of a primary PCa specimen with weak AKR1C3 staining (image 1) and three
CRPC specimens with different AKR1C3 staining intensities: strong (image 2), weak/inter-
mediate (image 3) and negative (image 4). For technical details, see text.
Figure 2. AKR1C3 levels in several prostate (cancer) cell lines. AKR1C3 protein levels in
cell lines were determined by Western blot analysis. β-Actin was used for normalization.
catalyzing conversion of adrenal andro-
gens are upregulated in prostate tumors
after ADT. In particular, AKR1C3 has
gained attention because of its stronger
expression both at the mRNA and protein
level in CRPC compared with normal
prostate, BPH or primary PCa (8,9,11,31).
However, only ~30% of CRPC patients in
our study displayed high AKR1C3 ex-
pression, which is in agreement with a
previous report (11,19). The limitation of
our study is the heterogeneity of previous
hormonal treatment of the CRPC group.
So further validation using tissue from
CRPC patients treated according to stan-
dard protocols is needed.
Our studies have shown that AKR1C3
mRNA and protein can be easily de-
tected by PCR and immunohistochem-
istry in biopsy and transurethral resec-
tion of the prostate material, respectively.
Even though our samples were divided
into two groups—frozen (RNA and
Western blot analysis) and paraffin em-
bedded (immunohistochemistry)—a cor-
relation between AKR1C3 mRNA and
protein level was consistent. Immunohis-
tochemistry showed that AKR1C3 was
expressed specifically in the carcinoma
cells and not in the stromal cells. The
specific upregulation of AKR1C3 in a
subset of CRPC cases makes it an attrac-
tive biomarker to select patients for ther-
apeutic intervention with AKR1C3.
We selected DuCaP as a model for in
vitro studies, because DuCaP cells ex-
press AKR1C3 at high levels, and the
cells express a wild-type AR (28). Wild-
type AR only can be activated by T
and/or DHT at nanomolar concentra-
tions. Therefore, DuCaP cells fail to pro-
liferate when they are cultured in me-
dium supplemented with DHEA as the
sole androgen source, unless DHEA is
first converted into T and DHT. We show
that DuCaP cells hardly grow in steroid-
free medium and that growth was stimu-
lated by adding DHEA. We also pro-
vided evidence that DHEA is converted
by the tumor cells into T and DHT. This
conversion could be blocked by inhibit-
ing AKR1C3 enzymatic activity with a
specific inhibitor INN.
Our data showed a downregulation of
the AKR1C3 protein upon increasing T
and DHT levels. Furthermore, AKR1C3
expression in the DuCaP-N cell line, a
DuCaP derivative cell line continuously
cultured in the presence of higher andro-
gen level (1 nmol/L R1881), expresses
threefold lower AKR1C3 protein than pa-
rental DuCaP cells. Consistent with our
studies, it was recently demonstrated by
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Figure 3. DHEA-induced DuCaP proliferation. (A) Schematic illustration of the metabolic conversion of DHEA into T and DHT. (B) DuCaP
cell proliferation in medium, supplemented with different concentrations of DHEA. Cells were grown for 16 d; then the fraction of viable
cells was determined using MTT assays and normalized to cells grown in d 0. Each experiment was done in triplicate. Statistical analysis
was performed by using one-way ANOVA, Dunnett correction test. *p < 0.05. (C) DuCaP cell proliferation in 100 nmol/L DHEA-containing
medium. Each experiment was done in triplicate. Statistical analysis was performed by using two-way ANOVA, Bonferroni correction test.
**p < 0.001. (D) Androgen levels measured in conditioned medium of DuCaP cells growing in medium supplemented with 100 nmol/L
DHEA. (E) AKR1C3 protein expression measured by Western blot in DuCaP cells cultured for the indicated times in medium supplemented
with 100 nmol/L DHEA. Statistical analysis was performed by using one-way ANOVA, Dunnett correction test. *p < 0.05. (A–E) All experi-
ments were performed at least two times. Standard error of the means are indicated by bars.
others that addition of synthetic andro-
gens had a negative effect on the expres-
sion of AKR1C3 (8). Therefore, high
AKR1C3 expression can be considered as
a marker of early adaptation to low an-
drogen levels by using the adrenal an-
drogen DHEA.
Interfering with AKR1C3 activity by
using INN resulted in an accumulation
of AND, because AKR1C3 no longer cat-
alyzes the reduction of AND to form T.
As a result of AKR1C3 inhibition, T and
DHT levels decreased and cell prolifera-
tion ceased. The decrease in viable cells
upon INN treatment was caused by the
induction of apoptosis, but was not asso-
ciated with a change in cell cycle pro-
gression. Reduced androgen levels have
already been related to apoptosis induc-
tion. (32) We were not able to measure
androstenediol generated by AKR1C3-
mediated reduction of DHEA because of
radioimmunoassay sensitivity limita-
tions. To the best of our knowledge, this
is a first study showing interference of
adrenal androgen DHEA conversion
through the AKR1C3 enzyme.
Inhibition of AKR1C3 enzyme activity
holds promise for the treatment of CRPC
patients in the future. One of the chal-
lenges in developing an AKR1C3 in-
hibitor is its >86% sequence identity with
the other human members of the AKR1C
subfamily, AKR1C1 and AKR1C2. The
latter two enzymes will reduce DHT to
less active metabolites, 3α-androstena-
diol and 3β-androstanediol. Therefore,
inhibition of these AKR1C activities
would inhibit DHT turnover and hence
promote proliferative signaling in the
prostate (26). Several compounds have
been developed and modified from sev-
eral analogs of nonsteroidal antiinflam-
matory drugs (NSAIDs) that effectively
inhibit AKR1C3 in biochemical assays
(33–36). Before INN or other compounds
can be used in CRPC patients, the effi-
cacy, toxicity and AKR1C3 specificity of
these compounds need to be determined
in cell culture and in vivo experiments.
Abiraterone, a specific CYP17A1 en-
zyme inhibitor reducing adrenal andro-
gen production, has shown a beneficial
effect as secondary treatment in CRPC
patients (14,37). This treatment, however,
will also accumulate steroids with miner-
alocorticoid properties upstream of
CYP17A1, resulting in its side effects,
such as hypertension, hypokalemia and
fluid overload. To prevent these side ef-
fects, abiraterone needs to be co-adminis-
tered with glucocorticoids and a miner-
alocorticoid inhibitor. Recent studies
show that prednisolone (a glucocorti-
coid) and mineralocorticoid inhibitors,
such as eplerenone and spironolactone,
can activate both wild-type and mutant
AR, which could lead to drug resistance
(38). Inhibition of AKR1C3, might have
less side effects than CYP17A1 inhibition
in the clinical setting, because AKR1C3
acts further downstream in the androgen
biosynthetic pathway and thus will not
lead to glucocorticoid reduction and
mineralocorticoid accumulation.
CONCLUSION
We show that AKR1C3 can be a bio-
marker to identify CRPC patients who
may benefit from therapies interfering
with AKR1C3 activity. Those patients
having high levels of AKR1C3 may be
amenable to novel forms of secondary
hormonal treatment. CRPC tumor cells
can convert adrenal androgens into ac-
tive growth-stimulating androgens 
(T and DHT), which can be blocked by
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Figure 4. INN inhibits DuCaP proliferation through interference with DHEA conversion result-
ing in the induction of apoptosis. (A) Inhibition of DuCaP cell proliferation by adding INN.
Each experiment was done in triplicate. ©, CSS only/no steroid; l, CSS + 100 nmol/L DHEA;
n, CSS + DHEA + 10 μmol/L INN; s, CSS + DHEA + 25 μmol/L INN. Statistical analysis was per-
formed by using two-way ANOVA, Bonferroni correction test, compared with the CSS +
DHEA group. **p < 0.001. (B) Reduction of androgen levels upon treatment of DuCaP cells
with INN. Androgen levels were measured at d 16. Statistical analysis was performed by
using one-way ANOVA, Dunnett correction test. *p < 0.05. Standard error of the means are
indicated by bars. (C) Apo-ONE caspase-3/7 assay showed that INN treatment for 2 h in-
duces cell apoptosis in a dose-dependent manner. Statistical analysis was performed by
using one-way ANOVA, Dunnett correction test. *p < 0.05. (D) Flow cytometry of propidium
iodide–stained DuCaP cells treated with INN for 48 h. Black line: CSS + 100 nmol/L DHEA;
blue line: CSS + DHEA + 10 μmol/L INN; red line: CSS + DHEA + 25 μmol/L INN. Arrow: sub-G1
apoptotic cell population. All experiments were performed at least two times.
interfering with AKR1C3 protein activity.
Therefore, novel AKR1C3 targeting
drugs may be potential drugs for second-
line hormonal treatment of CRPC
 patients.
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